Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza A (H1N1) 2009 Monovalent Vaccine + Influenza A (H1N1) Monovalent Vaccine Live-University of Rochester-2009 H1N1 influenza
- Development stage
- Unknown
- Lead developer
- University of Rochester
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
This sequential vaccination regimen consists of one dose of an inactivated monovalent H1N1 influenza vaccine (IIV) followed by one dose of a live attenuated monovalent H1N1 influenza vaccine (LAIV). It was evaluated by the University of Rochester in a Phase 4 clinical trial (NCT01081639) to study the immune response and safety in children aged 4-9 years during the 2009 H1N1 pandemic. The regimen aims to leverage the different immunological pathways of inactivated vaccines, which primarily induce systemic IgG antibodies, and live-attenuated vaccines, which mimic natural infection to stimulate mucosal IgA and cellular immune responses. Both components target the A/California/07/2009 (H1N1) strain.
- Brand names
- afluriafluzonefluviralmedimmune intranasal h1n1 (for the live, attenuated form)
- Other names
- IIV followed by LAIVInactivated H1N1 vaccine plus Live Attenuated H1N1 vaccineInfluenza A (H1N1) 2009 Monovalent Vaccine + Influenza A (H1N1) Monovalent Vaccine Live
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on Influenza A (H1N1) 2009 Monovalent Vaccine + Influenza A (H1N1) Monovalent Vaccine Live-University of Rochester-2009 H1N1 influenza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A (H1N1) 2009 Monovalent Vaccine + Influenza A (H1N1) Monovalent Vaccine Live-University of Rochester-2009 H1N1 influenza.